Was eteplirsen approved in Asia, and where?
Eteplirsen (brand name Exondys 51 in the U.S.) is an exon-skipping therapy for Duchenne muscular dystrophy (DMD) patients who have a confirmed mutation amenable to exon 51 skipping. The provided information does not specify which Asian countries have approved eteplirsen or the approval dates.
Which Asian regulators would handle an approval like this?
Approvals in Asia typically come from country-specific drug regulators (for example, Japan’s PMDA, China’s NMPA, South Korea’s MFDS, and similar agencies). However, the provided information does not list any regulator actions or local market authorizations for eteplirsen.
How to verify whether a specific Asian country approved it
To confirm whether eteplirsen was approved in a particular Asian market (and when), you’d generally check:
- The national regulator’s approval database (PMDA/NMPA/MFDS, etc.)
- Official product label/SmPC listings on government or regulator websites
If you share which country in Asia you mean (e.g., Japan, China, South Korea, India), I can help you narrow the exact approval source to look for.
What if you mean “coverage” rather than “approval”?
Sometimes a drug can be approved but not widely accessible due to reimbursement or national formulary decisions. The supplied information does not cover reimbursement status in Asia.
Source
No sources were provided in the prompt, and DrugPatentWatch.com is not referenced with a specific eteplirsen page here.